The Communication of Genetic Risk to Adolescent Daughters of Women With Breast Cancer
The purpose of this study is to first understand how MSKCC Clinical Genetics Service doctors talk to women with breast cancer about any genetic risks they might carry, and if they help women to think about what they might say, in turn, to their relatives, especially their daughters.
A second part of the study asks women for their opinions about when and how their daughters should be told about any genetic risks.
All of this will help us develop teaching methods to help our doctors improve the way they talk about genetic risk when women with breast cancer have adolescent daughters.
|Study Design:||Observational Model: Family-Based
Time Perspective: Prospective
|Official Title:||The Communication of Genetic Risk to Adolescent Daughters of Women With Breast Cancer|
- Is a demonstration of the effectiveness of the module in changing the behavior of clinicians after taking part in the communication skills module. [ Time Frame: conclusion of study ]
- To examine the views of women about the provision of genetic risk information to their daughters. [ Time Frame: conclusion of study ]
|Study Start Date:||December 2007|
|Study Completion Date:||January 2017|
|Primary Completion Date:||January 2017 (Final data collection date for primary outcome measure)|
focus group & questionaire
The group will discuss its views about how and when to talk about the risk of getting breast cancer. The focus group will be video recorded and the video recorded material will be later transcribed and carefully analyzed. In addition you will be asked to answer questions about yourself, such as education and marital status.
Behavioral: focus group & questionaire
The focus group will last about 90 minutes. However, your involvement in this study will last from the time you join until you read over the summary of what happened during the focus group and return your comments. This should be approximately 2 months. Patient will complete a questionnaire and we estimate total time for completion to be approximately 7 minutes.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00588705
|United States, New York|
|Memorial Sloan-Kettering Cancer Center|
|New York, New York, United States, 10065|
|Principal Investigator:||Smita Banerjee, PhD||Memorial Sloan Kettering Cancer Center|